Researchers developed a radioactive platinum-bisphosphonate complex (195mPt-BP) that selectively targets bone with high metabolic activity, showing potential for treating bone metastases. The compound accumulated in the bone tissue of mice with minimal off-target effects and slow release of platinum, suggesting a safer and more effective therapeutic strategy.

The authors acknowledge funding support from the NIRM, Netherlands Institute for Regenerative Medicine, and the Radboud Institute for Molecular Life Science (RIMLS), which could potentially represent a conflict of interest.

This study presents a novel and promising approach for targeted radionuclide therapy of bone metastases using a bone-seeking radioactive platinum-bisphosphonate complex. The in vivo experiments demonstrate specific accumulation of the compound in metabolically active bone, which is highly relevant for targeting bone metastases. The methodology is rigorous, including advanced imaging techniques like micro-SPECT/CT and LA-ICP-MS. However, some limitations exist, such as the small sample size, lack of direct therapeutic efficacy comparison, and limited toxicity assessment, which prevent a rating of 5.